"Excellent" Year For UCB In 1996

20 April 1997

Despite the first six months of 1996 being affected by an economicslowdown in the chemical industry, the Belgian firm UCB said it had a good year. Group turnover was 50.8 billion Belgian francs ($1.4 billion), compared with 51.7 billion francs a year earlier. If the sales of the packaging division are excluded - the unit was divested in 1996, consolidated turnover showed an increase of around 19%, says UCB.

1996 pretax profits were 6.9 billion francs, up 62.9%, and net profits were up 71.9% to 5.8 billion francs. Pretax profits included an exceptional item of 1.2 billion francs.

UCB said its prospects for 1997 are favorable, and profits should grow.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight